Euclid Advisors’s Amgen AMGN Stock Holding History

Euclid Advisors’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-17,270	Closed	-$2.63M	–	50
2016 Q2	$2.63M	Sell	17,270 -8,172	-32%	-$1.27M	0.11%	242
2016 Q1	$3.81M	Sell	25,442 -41,094	-62%	-$6.11M	0.14%	209
2015 Q4	$10.8M	Buy	+66,536	New	+$10.5M	0.33%	99
2015 Q3	–	Sell	-131,327	Closed	-$20.2M	–	235
2015 Q2	$20.2M	Sell	131,327 -144,843	-52%	-$23.2M	0.4%	78
2015 Q1	$44.1M	Buy	+276,170	New	+$43.5M	0.81%	22
2014 Q4	–	Sell	-386,230	Closed	-$54.3M	–	376
2014 Q3	$54.3M	Buy	386,230 +25,140	+7%	+$3.28M	0.39%	56
2014 Q2	$42.7M	Sell	361,090 -55,632	-13%	-$6.44M	0.3%	74
2014 Q1	$51.4M	Buy	416,722 +114,860	+38%	+$13.9M	0.39%	54
2013 Q4	$34.5M	Sell	301,862 -14,790	-5%	-$1.68M	0.29%	76
2013 Q3	$35.4M	Buy	316,652 +66,212	+26%	+$7.18M	0.36%	61
2013 Q2	$24.7M	Buy	+250,440	New	+$26M	0.31%	75

Other funds holding AMGN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Euclid Advisors's AMGN Position: Q3 2016 in Review

Euclid Advisors sold out of Amgen (AMGN) in Q3 2016, closing a stake of 17,270 shares — an estimated $2.63M sold.

Euclid Advisors first reported a position in AMGN in Q2 2013 and held it in 11 quarters. The position peaked at $54.3M in Q3 2014. 1,518 funds tracked by Wall St. Rank hold AMGN as of Q3 2016.

Euclid Advisors reported no remaining Amgen position as of Q3 2016 after selling out during the quarter.
Euclid Advisors sold 17,270 Amgen shares in Q3 2016, an estimated $2.63M.
Euclid Advisors first reported a position in Amgen in Q2 2013 and held it in 11 quarters.
Euclid Advisors's Amgen position peaked at $54.3M in Q3 2014.
1,518 funds tracked by Wall St. Rank held Amgen as of Q3 2016.

Based on Euclid Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.